COAG - CIK 0002114044
Hemab Therapeutics Holdings, Inc. trades as COAG and has a market capitalization of $1.17 B, making it the #2524 largest US-listed company by market value. This page tracks Hemab Therapeutics Holdings, Inc. through 38 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-21 |
| Quarterly report | 10-Q | 2026-05-21 |
| Major company event | 8-K | 2026-05-21 |
| Insider trade | 4 | 2026-05-14 |
| New insider ownership | 3 | 2026-05-14 |
| SCHEDULE 13G | - | 2026-05-11 |
| Insider trade | 4 | 2026-05-11 |
| SCHEDULE 13D | - | 2026-05-11 |
Hemab Therapeutics Announces $157 Million Series C Financing to Advance Next-Generation Treatments for Underserved Bleeding Disorders · Advancing ...
The largest companies sharing Hemab Therapeutics Holdings, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Hemab Therapeutics Holdings, Inc. (COAG) has a market capitalization of $1.17 B as of 2026-06-10, ranking #2524 among US-listed companies.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.